…
IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imaging contract research organization solutions, including imaging biomarkers, such as radiological reads, volumetric MRI, PET and SPECT, and advanced MRI; trial management; data analytics; post marketing surveillance and clinical diagnostics; and consultancy services. In addition, the company offers IXICO platform, an AI-enabled technology platform for neuroimaging data management and analysis. Its services are used for various therapeutic areas comprising Alzheimer's, Huntington's, Multiple Sclerosis, and Parkinson's diseases, as well as other rare neurological diseases, other Demyelinating disorders, and other Parkinsonian disorders. It has collaboration with Medidata to create neuroimaging clinical trials platform. The company is based in London, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
IXICO plc provides digital analytics and imaging services for neuroscience clinical trials, focusing on neurodegenerative diseases. Growth may be driven by rising demand for validated imaging and digital biomarkers, increasing neurology R&D, and adoption of data-driven endpoints. Investors may find appeal in its niche expertise, technology platform and recurring trial service exposure.
Material risks include cyclical biopharma R&D and client concentration, competition from larger CROs and analytics firms, biomarker validation and regulatory uncertainty, and limited liquidity as a smaller public company.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | -2.45M | -1.91M | -1.36M | 0.89M | 1.16M |
| Net income | -1.65M | -2.00M | -1.18M | 1.03M | 1.57M |
| Selling general administrative | 2.49M | 2.91M | 4.17M | 3.48M | 3.58M |
| Selling and marketing expenses | 1.67M | 1.40M | - | - | - |
| Gross profit | 3.18M | 2.71M | 3.27M | 5.24M | 6.02M |
| Reconciled depreciation | 0.41M | 0.47M | 0.62M | 0.64M | 0.61M |
| Ebit | -2.43M | -2.15M | - | 0.91M | 1.12M |
| Ebitda | -2.02M | -1.95M | - | 1.56M | 1.79M |
| Depreciation and amortization | 0.41M | 0.21M | - | - | - |
| Operating income | -2.55M | -2.15M | -1.44M | 0.76M | 1.16M |
| Other operating expenses | 9.09M | 7.92M | - | 0.69M | 0.45M |
| Interest expense | 0.02M | 0.03M | 0.03M | 0.03M | 0.02M |
| Tax provision | -0.80M | -0.09M | -0.18M | -0.15M | -0.41M |
| Interest income | 0.12M | 0.09M | 0.10M | 0.01M | 0.00M |
| Net interest income | 0.10M | 0.06M | 0.08M | -0.02M | -0.02M |
| Income tax expense | -0.80M | 0.09M | - | -0.15M | -0.41M |
| Total revenue | 6.53M | 5.77M | 6.67M | 8.64M | 9.19M |
| Total operating expenses | 5.74M | 4.87M | 8.10M | 7.88M | 8.03M |
| Cost of revenue | 3.35M | 3.06M | 3.40M | 3.40M | 3.17M |
| Total other income expense net | 0.10M | 0.25M | - | - | - |
| Net income from continuing ops | -1.65M | -2.00M | -1.18M | 1.03M | 1.57M |
| Net income applicable to common shares | - | - | - | 1.03M | 1.51M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 13.84M | 11.19M | 12.99M | 14.65M | 14.15M |
| Intangible assets | 7.18M | 6.37M | 6.15M | 4.59M | 2.71M |
| Other current assets | 0.80M | 0.49M | - | 0.10M | 0.11M |
| Total liab | 2.10M | 1.72M | 1.56M | 2.16M | 2.93M |
| Total stockholder equity | 11.74M | 9.46M | 11.43M | 12.49M | 11.22M |
| Other current liab | 1.74M | 1.15M | - | 0.85M | 0.53M |
| Common stock | 0.93M | 0.48M | - | 0.48M | 0.48M |
| Capital stock | 0.93M | 0.48M | 0.48M | 0.48M | 0.48M |
| Retained earnings | -10.78M | 7.46M | -7.36M | -6.23M | -7.34M |
| Other liab | - | - | - | 0.03M | 0.11M |
| Cash | 3.54M | 1.79M | 4.03M | 5.77M | 6.68M |
| Total current liabilities | 2.06M | 1.57M | 1.28M | 1.74M | 2.15M |
| Net debt | -3.36M | -1.47M | - | - | - |
| Short term debt | 0.15M | 0.16M | - | - | - |
| Short long term debt total | 0.18M | 0.31M | - | - | - |
| Other stockholder equity | 21.59M | 1.52M | - | -66.56M | -66.46M |
| Property plant equipment | - | - | - | 0.82M | 1.08M |
| Total current assets | 6.23M | 4.49M | 6.29M | 9.25M | 10.47M |
| Net tangible assets | - | - | - | 7.91M | 8.77M |
| Net receivables | 1.90M | 2.21M | 0.94M | 2.73M | 3.12M |
| Accounts payable | 0.07M | 0.08M | 0.09M | 0.25M | 0.73M |
| Accumulated other comprehensive income | 9.89M | 9.84M | - | - | - |
| Non currrent assets other | 0.26M | 0.01M | - | - | - |
| Non current assets total | 7.61M | 6.70M | 6.70M | 5.40M | 3.79M |
| Capital lease obligations | 0.18M | 0.31M | 0.39M | 0.52M | 0.60M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Investments | - | -0.38M | -1.86M | -2.24M | -2.15M |
| Change to liabilities | - | - | - | -0.70M | -0.37M |
| Total cashflows from investing activities | -0.75M | -0.38M | - | -2.24M | -2.15M |
| Net borrowings | - | - | - | -0.11M | -0.04M |
| Total cash from financing activities | 3.50M | -0.13M | - | -0.11M | 0.27M |
| Net income | -1.65M | -2.00M | -1.18M | 1.03M | 1.51M |
| Change in cash | 1.75M | -2.24M | -1.72M | -0.92M | -1.26M |
| Begin period cash flow | 1.79M | 4.03M | 5.77M | 6.68M | 7.95M |
| End period cash flow | 3.54M | 1.79M | 4.03M | 5.77M | 6.68M |
| Total cash from operating activities | -1.01M | -1.73M | 0.30M | 1.42M | 0.61M |
| Issuance of capital stock | 3.70M | 0.00M | 0.00M | 0.00M | 0.31M |
| Depreciation | 0.41M | 0.47M | 0.62M | 0.49M | 0.50M |
| Other cashflows from investing activities | -0.69M | -0.34M | - | 0.01M | 0.00M |
| Change to account receivables | 0.26M | -0.56M | - | 0.28M | -1.09M |
| Other cashflows from financing activities | -0.19M | -0.13M | - | - | - |
| Change to netincome | - | - | - | 0.17M | -0.05M |
| Capital expenditures | 0.87M | 0.47M | 1.96M | 0.19M | 0.17M |
| Change in working capital | 0.42M | -0.21M | 0.96M | -0.42M | -1.52M |
| Stock based compensation | 0.23M | 0.01M | 0.05M | 0.08M | 0.20M |
| Other non cash items | -0.41M | -0.01M | -0.43M | -0.29M | -0.19M |
| Free cash flow | -1.88M | -2.20M | -1.66M | -0.82M | -1.54M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PHYOF IXICO plc |
- -% |
0.07 | - | 41.49 | 23.18 | 0.26 | 0.40 | 4.14 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imaging contract research organization solutions, including imaging biomarkers, such as radiological reads, volumetric MRI, PET and SPECT, and advanced MRI; trial management; data analytics; post marketing surveillance and clinical diagnostics; and consultancy services. In addition, the company offers IXICO platform, an AI-enabled technology platform for neuroimaging data management and analysis. Its services are used for various therapeutic areas comprising Alzheimer's, Huntington's, Multiple Sclerosis, and Parkinson's diseases, as well as other rare neurological diseases, other Demyelinating disorders, and other Parkinsonian disorders. It has collaboration with Medidata to create neuroimaging clinical trials platform. The company is based in London, the United Kingdom.
| Name | Title | Year Born |
|---|---|---|
| Mr. Giulio Cerroni | CEO & Director | 1962 |
| Mr. Grant Nash | CFO, Company Sec. & Exec. Director | NA |
| Prof. Daniel Rueckert | Co-Founder & Member of Scientific Advisory Board | NA |
| Prof. Derek Lionel Glendon Hill | Co-Founder and Pres of Regulatory Science & External Relations | 1966 |
| Prof. David Hawkes | Co-Founder & Member of Scientific Advisory Board | NA |
| Prof. Joseph Hajnal | Co-Founder & Member of Scientific Advisory Board | NA |
| Mr. Marcus Thornton | Chief Operating Officer | NA |
| Mr. Mark Austin | Director of Technology | NA |
| Dr. Robin Wolz | Chief Scientific Officer | NA |
| Ms. Hannah Esfahanian | HR Mang. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.